open access

Vol 71, No 3 (2020)
Original Paper
Published online: 2020-03-26
Submitted: 2020-02-09
Accepted: 2020-03-15
Get Citation

Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes — [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience — do we need [18F]FDG PET/CT for qualification to PRRT?

Anna Zemczak, Maciej Kołodziej, Paweł Gut, Leszek Królicki, Beata Kos-Kudła, Grzegorz Kamiński, Marek Ruchała, Dariusz Pawlak, Jolanta Kunikowska
DOI: 10.5603/EP.a2020.0014
·
Pubmed: 32293704
·
Endokrynologia Polska 2020;71(3):240-248.

open access

Vol 71, No 3 (2020)
Original Paper
Published online: 2020-03-26
Submitted: 2020-02-09
Accepted: 2020-03-15

Abstract

Introduction: Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). The aim of the study was the evaluation of the role of [18F]FDG PET/CT in predicting response, progression-free survival (PFS) and overall survival (OS) after tandem therapy [90Y]Y/[177Lu]Lu-DOTATATE.

Material and methods: Seventy-five patients with histopathologically proven NET G1 and G2 were included in the study. Before treatment [68Ga]Ga-DOTATATE PET/CT and [18F]FDG PET/CT was performed. Patients were treated with [90Y]Y/[177Lu]Lu-DOTATATE (1:1) with mixed amino-acid infusion for kidney protection.

Results: Progression-free survival was 22.2 months for [18F]FDG-positive patients and 59.3 months for [18F]FDG-negative patients (p = 0.003). The OS from diagnosis (OS-D) and from the start of PRRT (OS-T) was not reached in [18F]FDG-negative patients, and in [18F]FDG-positive patients it was 71.8 months and 55.8 months, respectively. The observed overall one-year survival in [18F]FDG-positive vs. [18F]FDG-negative patients was 96.8% vs. 99.1%, two-year survival was 88.9% vs. 96%, and five-year survival was 58.8% vs. 88%, respectively. The one-year and two-year risk of progression was 15% vs. 58.9% in [18F]FDG-positive patients and 11% vs. 32% in [18F]FDG-negative patients. The objective response rate (ORR) [18F]FDG-positive vs. [18F]FDG-negative patients was 41.7% vs. 17%.

Conclusions: [18F]FDG-positive patients have statistically significant shorter survival parameters than [18F]FDG-negative patients. The risk of progression in [18F]FDG-positive vs. [18F]FDG-negative patients in one-year follow-up is comparable, whereas in two-year follow-up it is nearly two times higher for [18F]FDG PET/CT-positive patients. 

Abstract

Introduction: Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). The aim of the study was the evaluation of the role of [18F]FDG PET/CT in predicting response, progression-free survival (PFS) and overall survival (OS) after tandem therapy [90Y]Y/[177Lu]Lu-DOTATATE.

Material and methods: Seventy-five patients with histopathologically proven NET G1 and G2 were included in the study. Before treatment [68Ga]Ga-DOTATATE PET/CT and [18F]FDG PET/CT was performed. Patients were treated with [90Y]Y/[177Lu]Lu-DOTATATE (1:1) with mixed amino-acid infusion for kidney protection.

Results: Progression-free survival was 22.2 months for [18F]FDG-positive patients and 59.3 months for [18F]FDG-negative patients (p = 0.003). The OS from diagnosis (OS-D) and from the start of PRRT (OS-T) was not reached in [18F]FDG-negative patients, and in [18F]FDG-positive patients it was 71.8 months and 55.8 months, respectively. The observed overall one-year survival in [18F]FDG-positive vs. [18F]FDG-negative patients was 96.8% vs. 99.1%, two-year survival was 88.9% vs. 96%, and five-year survival was 58.8% vs. 88%, respectively. The one-year and two-year risk of progression was 15% vs. 58.9% in [18F]FDG-positive patients and 11% vs. 32% in [18F]FDG-negative patients. The objective response rate (ORR) [18F]FDG-positive vs. [18F]FDG-negative patients was 41.7% vs. 17%.

Conclusions: [18F]FDG-positive patients have statistically significant shorter survival parameters than [18F]FDG-negative patients. The risk of progression in [18F]FDG-positive vs. [18F]FDG-negative patients in one-year follow-up is comparable, whereas in two-year follow-up it is nearly two times higher for [18F]FDG PET/CT-positive patients. 

Get Citation

Keywords

PRRT; [90Y]Y/[177Lu]Lu-DOTATATE; [18F]FDG PET/CT; tandem therapy; neuroendocrine tumours

About this article
Title

Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes — [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience — do we need [18F]FDG PET/CT for qualification to PRRT?

Journal

Endokrynologia Polska

Issue

Vol 71, No 3 (2020)

Pages

240-248

Published online

2020-03-26

DOI

10.5603/EP.a2020.0014

Pubmed

32293704

Bibliographic record

Endokrynologia Polska 2020;71(3):240-248.

Keywords

PRRT
[90Y]Y/[177Lu]Lu-DOTATATE
[18F]FDG PET/CT
tandem therapy
neuroendocrine tumours

Authors

Anna Zemczak
Maciej Kołodziej
Paweł Gut
Leszek Królicki
Beata Kos-Kudła
Grzegorz Kamiński
Marek Ruchała
Dariusz Pawlak
Jolanta Kunikowska

References (32)
  1. Kos-Kudła B, Blicharz-Dorniak J, Strzelczyk J, et al. Consensus Conference, Polish Network of Neuroendocrine Tumours. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2013; 64(6): 418–443.
  2. Plöckinger U, Rindi G, Arnold R, et al. European Neuroendocrine Tumour Society. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004; 80(6): 394–424.
  3. Ramage JK, Ahmed A, Ardill J, et al. UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012; 61(1): 6–32.
  4. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18): 3063–3072.
  5. Ramage JK, De Herder WW, Delle Fave G, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology. 2016; 103(2): 139–143.
  6. Kvols LK, Brendtro KL. North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process. Pancreas. 2010; 39(6): 705–706.
  7. Maroun J, Kocha W, Kvols L, et al. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol. 2006; 13(2): 67–76.
  8. Amin MB, Edge S, Greene F. AJCC Cancer Staging Manual. Eighth Edition. Springer 2017.
  9. Brierley JD, Gospodarowicz MK, Wittekind CT. TNM Classification of Malignant Tumours. Eighth Edition. Wiley Blackwell 2017.
  10. Binderup T, Knigge U, Loft A, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med. 2010; 51(5): 704–712.
  11. Severi S, Nanni O, Bodei L, et al. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013; 40(6): 881–888.
  12. July M, Santhanam P, Giovanella L, et al. Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes. Clin Physiol Funct Imaging. 2018; 38(1): 4–9.
  13. Sansovini M, Severi S, Ianniello A, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with Lu-D OTATATE. Eur J Nucl Med Mol Imaging. 2017; 44(3): 490–499.
  14. Binderup T, Knigge U, Loft A, et al. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010; 16(3): 978–985.
  15. Kunikowska J, Zemczak A, Górska M, et al. TeleNEN as a telemedicine model for neuroendocrine neoplasm management in case of Meckel's diverticulum NET. Endokrynol Pol. 2018; 69(3): 313–317.
  16. Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003; 30(1): 9–15.
  17. Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011; 38(10): 1788–1797.
  18. Kunikowska J, Pawlak D, Bąk MI, et al. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with Y/Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Ann Nucl Med. 2017; 31(5): 347–356.
  19. Kunikowska J, Zemczak A, Kołodziej M, et al. Tandem peptide receptor radionuclide therapy using Y/Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. Eur J Nucl Med Mol Imaging. 2020; 47(4): 922–933.
  20. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13): 2124–2130.
  21. Delpassand ES, Samarghandi A, Zamanian S, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014; 43(4): 518–525.
  22. Parghane RV, Talole S, Prabhash K, et al. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Clin Nucl Med. 2017; 42(6): 428–435.
  23. Sabet A, Dautzenberg K, Haslerud T, et al. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015; 42(8): 1238–1246.
  24. Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011; 38(12): 2125–2135.
  25. van Essen M, Krenning EP, Bakker WH, et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging. 2007; 34(8): 1219–1227.
  26. Bodei L, Cremonesi M, Kidd M, et al. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Thorac Surg Clin. 2014; 24(3): 333–349.
  27. Nicolini S, Severi S, Ianniello A, et al. Investigation of receptor radionuclide therapy with Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. Eur J Nucl Med Mol Imaging. 2018; 45(6): 923–930.
  28. Ianniello A, Sansovini M, Severi S, et al. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Eur J Nucl Med Mol Imaging. 2016; 43(6): 1040–1046.
  29. Strosberg J, El-Haddad G, Wolin E, et al. NETTER-1 Trial Investigators. Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2): 125–135.
  30. Ezziddin S, Khalaf F, Vanezi M, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014; 41(5): 925–933.
  31. Zhang J, Kulkarni HR, Singh A, et al. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. J Nucl Med. 2019; 60(3): 377–385.
  32. Rogowski W, Wachuła E, Gorzelak A, et al. Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis. Endokrynol Pol. 2019; 70(4): 313–317.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl